Quince Therapeutics (NASDAQ:QNCX) Raised to Strong-Buy at RODMAN&RENSHAW

Quince Therapeutics (NASDAQ:QNCX) was upgraded by stock analysts at RODMAN&RENSHAW to a “strong-buy” rating in a research note issued on Tuesday, Zacks.com reports.

A number of other equities analysts have also weighed in on the company. Rodman & Renshaw started coverage on Quince Therapeutics in a research note on Tuesday. They set a “buy” rating and a $11.00 price objective for the company. EF Hutton Acquisition Co. I upgraded Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd.

Quince Therapeutics Stock Performance

QNCX opened at $1.18 on Tuesday. The company has a current ratio of 6.15, a quick ratio of 6.15 and a debt-to-equity ratio of 0.29. Quince Therapeutics has a 12-month low of $0.51 and a 12-month high of $1.43. The firm has a 50 day moving average of $0.77 and a two-hundred day moving average of $0.80. The firm has a market capitalization of $50.99 million, a PE ratio of -1.55 and a beta of 0.86.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter.

Insider Activity at Quince Therapeutics

In other news, CEO Dirk Thye bought 77,500 shares of the stock in a transaction dated Thursday, August 29th. The shares were acquired at an average cost of $0.69 per share, with a total value of $53,475.00. Following the purchase, the chief executive officer now directly owns 766,941 shares in the company, valued at $529,189.29. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, President Charles S. Ryan purchased 48,387 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were purchased at an average price of $0.65 per share, with a total value of $31,451.55. Following the purchase, the president now owns 122,461 shares of the company’s stock, valued at $79,599.65. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Dirk Thye acquired 77,500 shares of Quince Therapeutics stock in a transaction on Thursday, August 29th. The shares were bought at an average price of $0.69 per share, with a total value of $53,475.00. Following the completion of the transaction, the chief executive officer now directly owns 766,941 shares of the company’s stock, valued at $529,189.29. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 158,887 shares of company stock worth $105,609. 16.80% of the stock is owned by company insiders.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.